Canaccord lowered the firm's price target on DocGo to $1 from $1.50 and keeps a Hold rating on the shares. The firm updated is model following mixed Q4 results as revenue topped the high end of its guidance. DocGo has significant work left to do to scale its go-forward Mobile Health business and rightsize its cost structure to regain adj-EBITDA profitability targeted in 2H 2026. The formal process exploring strategic alternatives may deliver a positive outcome for shareholders, but fundamentally, Canaccord maintains its "show me" stance.
